Literature DB >> 22029192

Autoantibodies against inosine-5'-monophosphate dehydrogenase 2--characteristics and prevalence in patients with HCV-infection.

H P Seelig1, H Appelhans, O Bauer, M Blüthner, K Hartung, P Schranz, D Schultze, Claudia A Seelig, M Volkmann.   

Abstract

BACKGROUND: Indirect immunofluorescence (IIFT) on in house HEp-2 cell preparations revealed a novel antibody giving a granular cytoplasmic pattern not described before, which on two commercial cell preparations revealed a "rings and rods" pattern. This pattern was also observed in four HCV-RNA carriers and prompted the identification of the reactive antigen and the evaluation of the antibody prevalence in HCV-RNA carriers and control groups.
METHODS: The antigen's molecular weight was determined by radioimmunoprecipitation of 35S-methionine labeled cell proteins. Expression library screening and sequencing was performed by standard techniques using an oligo(dT)-primed human HeLa cell cDNA expression library. Antibodies against the novel antigen Inositol-5'-monophosphatdehydrogenase 2 (IMPDH2) were analyzed by IIFT, western blot, line blot, and radioimmunoprecipitation assay (RIPA). IIFT was performed on commercial HEp-2 cells and cells cultivated in house for 24 - 60 hours, with or without the IMPDH2 inhibitors mycophenolic acid (MPA) or ribavirin, and subjected to various fixation conditions. Western and line blots were performed with IMPDH2 synthesized in E. coli, RIPA with 35S-methionine-IMPDH2 from in vitro transcription/translation products. Sera screened were positive for HCV-RNA (108), HBV-DNA (100), anti-mitochondrial (31), anti-actin (42), and anti-nuclear antibodies (51) and negative for HCV-RNA (100) and blood donors (100).
RESULTS: IMPDH2 is capable of considerable intracellular rearrangements (upon action of inhibitors like MPA and ribavirin), which explains the contrasting immunofluorescence patterns in cells from different sources. By RIPA, proven to be the sole assay suitable for screening of anti-IMPDH2 in human sera, autoantibodies were found in 35.2% of HCV-RNA carriers and in low concentrations in 31% of anti-actin positive patients suspicious of autoimmune hepatitis. Antibodies reacted preferentially with conformational epitopes. Compared to the low concentration of anti-IMPDH2 found in other disease groups, high antibody concentrations were observed in HCV-RNA carriers.
CONCLUSIONS: The common occurrence of anti-IMPDH2 in HCV-RNA carriers may be related to ribavirin therapy, causing intracellular aggregation of IMPDH2 thereby altering its immunogenicity. In this study the "rods and rings" immunofluorescence pattern observed could be ascribed to anti-IMPDH2. Anti-IMPDH2 may cause difficulties in interpretation of immunofluorescence patterns in routine autoantibody testing.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22029192

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  16 in total

Review 1.  Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy.

Authors:  Gerson Dierley Keppeke; S John Calise; Edward K L Chan; Luis Eduardo C Andrade
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

2.  Temporal evolution of human autoantibody response to cytoplasmic rods and rings structure during anti-HCV therapy with ribavirin and interferon-α.

Authors:  Gerson Dierley Keppeke; Minoru Satoh; Maria Lucia Gomes Ferraz; Edward K L Chan; Luís Eduardo C Andrade
Journal:  Immunol Res       Date:  2014-10       Impact factor: 2.829

3.  Autoantibodies against "rods and rings"-related IMPDH2 in hepatitis C genotype 1 and DAA therapy in a "real life" cohort.

Authors:  Werner Dammermann; Susanne Polywka; Inga Dettmann; Swantje Mindorf; Lars Komorowski; Malte Wehmeyer; Julian Schulze Zur Wiesch; Winfried Stöcker; Stefan Lüth
Journal:  Med Microbiol Immunol       Date:  2017-08-16       Impact factor: 3.402

4.  Differential reactivity to IMPDH2 by anti-rods/rings autoantibodies and unresponsiveness to pegylated interferon-alpha/ribavirin therapy in US and Italian HCV patients.

Authors:  Wendy C Carcamo; Angela Ceribelli; S John Calise; Claire Krueger; Chen Liu; Massimo Daves; Danilo Villalta; Nicola Bizzaro; Minoru Satoh; Edward K L Chan
Journal:  J Clin Immunol       Date:  2012-10-26       Impact factor: 8.317

5.  Glutamine deprivation initiates reversible assembly of mammalian rods and rings.

Authors:  S John Calise; Wendy C Carcamo; Claire Krueger; Joyce D Yin; Daniel L Purich; Edward K L Chan
Journal:  Cell Mol Life Sci       Date:  2014-01-30       Impact factor: 9.261

6.  The value of anti-rods and rings antibodies in patients with nonhepatitis virus infection: A single-center retrospective study from Southwest China.

Authors:  Naidan Zhang; Chaixia Ji; Hao Yang; Lihong Liu; Xiao Bao; Yusha Zhou; Chengliang Yuan
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

7.  Longitudinal study of a human drug-induced model of autoantibody to cytoplasmic rods/rings following HCV therapy with ribavirin and interferon-α.

Authors:  Gerson Dierley Keppeke; Eunice Nunes; Maria Lucia Gomes Ferraz; Eduardo Antônio Benedito Silva; Celso Granato; Edward K L Chan; Luís Eduardo C Andrade
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

Review 8.  Anti-rods/rings: a human model of drug-induced autoantibody generation.

Authors:  S John Calise; Gerson D Keppeke; Luis E C Andrade; Edward K L Chan
Journal:  Front Immunol       Date:  2015-02-05       Impact factor: 7.561

9.  Microinjection of specific anti-IMPDH2 antibodies induces disassembly of cytoplasmic rods/rings that are primarily stationary and stable structures.

Authors:  Gerson Dierley Keppeke; Luís Eduardo C Andrade; Scott S Grieshaber; Edward K L Chan
Journal:  Cell Biosci       Date:  2015-01-05       Impact factor: 7.133

10.  Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection.

Authors:  Laura M Stinton; Robert P Myers; Carla S Coffin; Marvin J Fritzler
Journal:  BMC Gastroenterol       Date:  2013-03-19       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.